CARDIOVASCULAR
hamburger
BACK
Clinical Evidence

Request a free demonstration

Download the Stent Deployment Guide

Unmatched 1-Year Patency & 3-Year Freedom From TLR

The Supera™ Stent has been studied in over 2,000 patients worldwide in the SUPERB trial and 16 retrospective studies. Notably, in all of the 17 studies, the Supera™ Peripheral Stent showed durable results with zero fractures at 1 year.1,15-30

SUPERB Trial

At 1 year the Supera™ Stent demonstrated primary patency of 91% when nominally* deployed. At 3 years, freedom from targeted lesion revascularization (TLR) was 94% when nominally* deployed.1

91% patency at 1 year
PATENCY (K-M) AT 1 YEAR

When nominally deployed*

94% freedom from TLR at 3 years
FREEDOM FROM TLR AT 3 YEARS

When nominally deployed*

*Nominal deployment is defined as the stent length upon deployment being within +/- 10% of the labeled stent length. These data are from a non-powered post-hoc analysis. KM = Kaplan-Meier.

Unmatched Clinical Outcomes

Supera Stent has demonstrated unmatched clinical outcomes in comparison to other US pivotal trial results which primarily included simple lesions.*,1-12

1-Year Patency (KM)   3-Year Freedom from TLR
91% Supera™ Stent
Nominal1		   94% Supera™ Stent
Nominal1
87% Eluvia‡12   Not Reported Eluvia‡
84% Zilver PTX‡2   84% Zilver PTX‡2
83% Misago‡11   Not Available Misago‡
81% LifeStent‡3   76% LifeStent‡4
80% S.M.A.R.T.‡5   79% S.M.A.R.T.‡6
77% EverFlex‡7   70% EverFlex‡8
74% Innova‡9   Not Reported Innova‡
67% Pulsar‡10   Not Reported Pulsar‡

* Study reported with a majority as Trans-Atlantic Inter-Society Consensus Document (TASC) A&B lesion and/or majority as Rutherford Class 2 and 3.

NOTE: Results from clinical trials are not directly comparable. Information provided for educational purposes only.

Consistent Patency Regardless of Lesion Length

With some peripheral stents, increasing lesion lengths can lead to decreasing patency rates.31 The Supera™ Stent stands apart for its consistently high patency rates in lesions spanning lengths from 5.3 cm up to 28.0 cm*.

uniformly high patency rates from short to long lesions

*Published data was included if lesion length and patency were both available.

Note: Results from different clinical trials are not directly comparable. Information provided for educational purposes only.

Excellent Patency in Both Simple and Complex Lesions

Whether treating simple (TASC A&B) or complex (TASC C&D) lesions, the Supera™ Stent is associated with impressive, consistent patency performance data.13-15,32

Simple
Simple lesion Trial/Study MUNICH REGISTRY13 SUPERB32
Lesion Length 5.3cm 7.8cm
TASC A&B Lesions 100% 94%
1-Yr
Patency		 86.7% 90.5%
Sites Single Center Multicenter (46 sites)
# Patients 70 264

TASC: Trans-Atlantic Inter-Society Consensus

Complex
Complex Lesion Trial/Study ST. LOUIS15 SUPERSUB14
Lesion Length 5.3cm 7.8cm
TASC C&D Lesions 78% 100%
CTOs Unknown 100%
1-Yr
Patency		 85.6% 94.1%
Sites Single Center Single Center
# Patients 48 34

TASC: Trans-Atlantic Inter-Society Consensus

  • REFERENCES
    1. Garcia L. et al., Catheterization and Cardiovascular Interventions 2017 Jun 1;89(7):1259-1267.
    2. Dake M. et al., Circulation. 2016;133:1472-1483.
    3. Laird J. et al., Circ Cardiovasc Interv. 2010;3:267-276.
    4. Laird J et al., J Endovasc Ther. 2012;19:1–9.
    5. S.M.A.R.T. Control IFU.
    6. Jaff, M., SMART Nitinol Self-Expanding Stent in the Treatment of Obstructive Superficial Femoral Artery Disease:  Three-year Clinical Outcomes from the STROLL Trial. ISET 2014.
    7. Matsumura J et al., J Vasc Surg 2013;58:73-83.
    8. Rocha-Singh, K., 3-Year Results of the DURABILITY II Study. VIVA 2013.
    9. US Innova IFU.
    10. US Pulsar IFU.
    11. Ohki T. et al. J Vasc Surg. 2016 Feb;63(2):370-6.
    12. Gray W. et al., Lancet 2018;392:1541-51.
    13. Treitl, K.M., et al. European Radiology.2017; 10.1007.
    14. Palena L.M. et al. Catheterization and Cardiovascular Intervention.2016.
    15. Brescia AA. et al., J Vasc Surg. 2015 Jun;61(6):1472-8
    16. George JC. et al., J Vasc Interv Radiol. 2014 Jun;25(6):954-61.
    17. Montero-Baker M. et al., J Vasc Surg. 2016 Oct;64(4):1002-8.
    18. Scheinert D. et al., J Endovasc Ther. 2011 Dec;18(6):745-52.
    19. Werner M. et al., EuroIntervention. 2014 Nov;10(7):861-8.
    20. San Norberto EM. et al., Ann Vasc Surg. 2017 May;41:186-195.
    21. Chan YC. et al., J Vasc Surg. 2015 Nov;62(5):1201-9.
    22. Dumantepe M. Vasc Endovascular Surg. 2017 Jul;51(5):240-246.
    23. Goltz JP. et al., J Endovasc Ther. 2012 Jun;19(3):450-6.
    24. León LR Jr. et al., J Vasc Surg. 2013 Apr;57(4):1014-22.
    25. Myint M. et al., J Endovasc Ther. 2016 Jun;23(3):433-41.
    26. Palena LM. et al., J Endovasc Ther. 2018 Oct;25(5):588-591.
    27. Scheinert D. et al., JACC Cardiovasc Interv. 2013 Jan;6(1):65-71.
    28. Steiner S. et al., J Endovasc Ther. 2016 Apr;23(2):347-55.
    29. Teymen B. et al., Vascular. 2018 Feb;26(1):54-61.
    30. Bhatt H. et al., Cardiovasc Revasc Med. 2018 Jul;19(5 Pt A):512-515.
    31. Shroë H. Superficial femoral artery PTA or stenting? 5-Year results. CIRSE 2011; Munich, Germany
    32. Garcia L. et al. Circ Cardiovasc Interv. 2015; 8:e00937.
Important Safety Information

MAT-2008210 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

Precautions


Please be sure to read it.

The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.

The information provided here is not intended to provide information to patients and the general public.



Are you a healthcare professional?

 

Test

yesno